Finish strong.

How hard should we push patients to complete their total course of neoadjuvant chemoradiation for rectal cancer?—when they do it, that is. This secondary analysis of the phase 3 CAO/ARO/AIO-04 trial reveals that roughly two-thirds of patients complete all planned neoadjuvant therapy which was associated with improved disease-free survival at 3 years compared to those who received less than planned, even those who received at least ≥45 Gy (of a planned 50.4 Gy) and  ≥80% of concurrent chemo. | Diefenhardt, JAMA Oncol 2020


Popular Posts